ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

M5542

A development code.

Its studies are mostly in Eczema, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 1, since Aug 22, 20242 company-led studies, 1 open or runningNext primary completion: Aug 14, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany21 open or runningphase 1since Aug 22, 2024Aug 22, 2024Aug 14, 2028phase 1 · NCT07932795

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2024First study: phase 1 study in HealthyFirst studyNCT06577337 · 49 enrolled · Germany
  2. Nov 5, 2026Phase 1 study in EczemaNCT07932795 · 56 planned · Germany

Ahead

  1. Aug 14, 2028Primary completion: phase 1 study in EczemaNCT07932795

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07932795Eczema · Germany1Not yet recruitingAug 14, 202856
NCT06577337Healthy · Germany1SuspendedDec 18, 202749

How it is read

Names in the registry

  • “M5542”, 2 entries

Codes read as this program: M5542.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.